Product Information
ABILIFY MAINTENA ER 400 MG SYR is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $2853.2457 per EA under NDC 59148007280. Its NADAC has been published 585 times since Jul 22, 2015.
FDA first approved this application on Feb 28, 2013.
The High Outlier badge above means this manufacturer's average price in the aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148007280
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202971FDA Approved
2/28/2013
On Market Since
10/8/2014
Price Statistics
The NADAC for ABILIFY MAINTENA ER 400 MG SYR has been published 585 times since Jul 22, 2015, and over the history we have for it it has risen 80.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2853.2457 per EA |
|---|---|
| All-time high | $2859.9740 (May 13, 2026) |
| All-time low | $1582.1289 (Jul 22, 2015) |
| 52-week high | $2859.9740 |
| 52-week low | $2776.0905 |
| Median price | $2281.1341 |
| Average price | $2281.8748 |
| Largest weekly change | +6.9% (Jan 26, 2022) |
| Weeks tracked | 585 |
| Tracking since | Jul 22, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Otsuka America Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
aripiprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ABILIFY MAINTENA ER 400 MG SYR?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY MAINTENA ER 400 MG SYR, manufactured by Otsuka America Pharmaceutical Inc., is $2853.2457 per EA (NDC 59148007280), effective Sep 30, 2026.
How has the price of ABILIFY MAINTENA ER 400 MG SYR changed over time?
Over the history we have for it, the NADAC for ABILIFY MAINTENA ER 400 MG SYR has risen 80.3%. It has been tracked across 585 weekly CMS publications since Jul 22, 2015.
What are the highest and lowest recorded NADAC prices for ABILIFY MAINTENA ER 400 MG SYR?
Since Jul 22, 2015, the NADAC for ABILIFY MAINTENA ER 400 MG SYR has ranged from a low of $1582.1289 (Jul 22, 2015) to a high of $2859.9740 (May 13, 2026), with a median of $2281.1341 per EA.
Are there cheaper alternatives to ABILIFY MAINTENA ER 400 MG SYR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ABILIFY MAINTENA ER 300 MG SYR, is $2139.0868 per EA — about 25% below ABILIFY MAINTENA ER 400 MG SYR.
Who manufactures ABILIFY MAINTENA ER 400 MG SYR?
ABILIFY MAINTENA ER 400 MG SYR (NDC 59148007280) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.